← Back to guidelines
Neurology31 papers

Metastatic malignant glioma

Last edited: 4/10/2026

Overview

Metastatic malignant glioma refers to the spread of a primary brain tumor originating from glial cells to other parts of the brain or central nervous system. These tumors present complex palliative care needs due to their life-limiting nature and potential for neurological deterioration 3.

Diagnosis

No information on diagnosis was provided in the abstracts.

Management

  • Surgery is a reasonable option for patients with brain metastases, particularly for large tumors with mass effect 1.
  • Multidisciplinary discussion with neurosurgery is conditionally recommended to consider surgical resection for tumors causing mass effect and/or greater than 4 cm 2.
  • For symptomatic brain metastases, upfront local therapy is strongly recommended regardless of systemic therapy 12.
  • For asymptomatic brain metastases, local therapy should not be deferred unless specifically recommended, based on a multidisciplinary discussion of potential benefits and harms 1.
  • For asymptomatic brain metastases without systemic therapy options, stereotactic radiosurgery (SRS) alone is recommended for patients with one to four unresected brain metastases (excluding small-cell lung carcinoma) 1.
  • SRS alone to the surgical cavity is recommended for patients with one to two resected brain metastases 1.
  • SRS, whole brain radiation therapy, or their combination are reasonable options for asymptomatic brain metastases 1.
  • Palliative care should be integrated early for patients with glioma to reduce symptom burden and improve quality of life 3.
  • Special Populations

    No information on special populations was provided in the abstracts.

    Key Recommendations

  • For patients with limited brain metastases and Eastern Cooperative Oncology Group performance status 0 to 2, SRS is strongly recommended 2. (Evidence: Strong)
  • For patients with symptomatic brain metastases, upfront local therapy is strongly recommended 2. (Evidence: Strong)
  • Multidisciplinary discussion with neurosurgery is conditionally recommended to consider surgical resection for all tumors causing mass effect and/or that are greater than 4 cm 2. (Evidence: Moderate)
  • For patients with asymptomatic brain metastases eligible for central nervous system-active systemic therapy, multidisciplinary and patient-centered decision-making is recommended to determine if local therapy may be safely deferred 2. (Evidence: Moderate)
  • Surgery is a reasonable option for patients with brain metastases 1. (Evidence: Moderate)
  • Palliative care should be initiated early for adult patients with glioma to address complex needs and improve quality of life 3. (Evidence: Expert opinion)
  • References

    1 Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D et al.. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022. link 2 Gondi V, Bauman G, Bradfield L, Burri SH, Cabrera AR, Cunningham DA et al.. Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Practical radiation oncology 2022. link 3 Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Rudà R et al.. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. The Lancet. Oncology 2017. link30345-5)

    Original source

    1. [1]
      Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
    2. [2]
      Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.Gondi V, Bauman G, Bradfield L, Burri SH, Cabrera AR, Cunningham DA et al. Practical radiation oncology (2022)
    3. [3]
      European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma.Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Rudà R et al. The Lancet. Oncology (2017)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG